|
|
Volumn 303, Issue 14, 2010, Pages 1353-1354
|
|
FDA offers advice to reduce risks of long-acting β-agonists in asthma care
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BUDESONIDE PLUS FORMOTEROL;
CORTICOSTEROID;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
FORMOTEROL;
LONG ACTING BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
SALMETEROL;
UNCLASSIFIED DRUG;
ADD ON THERAPY;
ADJUVANT THERAPY;
ASTHMA;
BREATHING DISORDER;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DISEASE CONTROL;
DISEASE EXACERBATION;
DRUG EFFICACY;
DRUG FATALITY;
DRUG MANUFACTURE;
DRUG SAFETY;
FATALITY;
FOOD AND DRUG ADMINISTRATION;
HOSPITALIZATION;
HUMAN;
INHALER;
LONG TERM CARE;
META ANALYSIS;
PATIENT CARE;
PHYSICIAN;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK FACTOR;
RISK REDUCTION;
SHORT SURVEY;
SYSTEMATIC REVIEW;
TREATMENT DURATION;
TREATMENT INDICATION;
DRUG INTERACTION;
DRUG LABELING;
NOTE;
UNITED STATES;
ADRENAL CORTEX HORMONES;
ADRENERGIC BETA-AGONISTS;
ASTHMA;
DRUG INTERACTIONS;
DRUG LABELING;
HUMANS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 77950894767
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2010.357 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|
